Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts, 02115-5000, USA.
Institut de Recherche en Cancérologie de Montpellier IRCM, INSERM U1194, ICM, Université de Montpellier, Montpellier, France.
Pharm Res. 2018 Mar 8;35(4):91. doi: 10.1007/s11095-018-2349-x.
The main purpose of this study was to formulate an oil-in-water nanoemulsion of a next generation taxoid DHA-SBT-1214 and evaluate its biodistribution and pharmacokinetics.
DHA-SBT-1214 was encapsulated in a fish oil containing nanoemulsion using a high pressure homogenization method. Following morphological characterization of the nanoemulsions, qualitative and quantitative biodistribution was evaluated in naïve and cancer stem cell-enriched PPT-2 human prostate tumor bearing mice.
DHA-SBT-1214 was successfully encapsulated up to 20 mg/ml in the nanoemulsion formulation and had an average oil droplet size of 200 nm. Using a DiR near infra-red dye encapsulated nanoemulsion, we have shown the delivery of nanoemulsion to mouse tumor region. By quantitative analysis, DHA-SBT-1214 encapsulated nanoemulsion demonstrated improved pharmacokinetic properties in plasma and different tissues as compared to its solution form. Furthermore, the nanoemulsions were stable and had slower in vitro drug release compared to its solution form.
The results from this study demonstrated effective encapsulation of the drug in a nanoemulsion and this nanoemulsion showed sustained plasma levels and enhanced tumor delivery relative to the solution form.
本研究的主要目的是制备一种新型紫杉烷类药物 DHA-SBT-1214 的水包油纳米乳,并评价其体内分布和药代动力学。
采用高压均质法将 DHA-SBT-1214 包封于含有鱼油的纳米乳中。对纳米乳进行形态学特征描述后,在未处理和富含肿瘤干细胞的 PPT-2 人前列腺肿瘤荷瘤小鼠中进行定性和定量的体内分布评价。
DHA-SBT-1214 成功地包封在纳米乳制剂中,浓度高达 20mg/ml,平均油滴大小为 200nm。使用包封 DiR 近红外染料的纳米乳,我们已经证明了纳米乳向小鼠肿瘤部位的递送。通过定量分析,与溶液形式相比,DHA-SBT-1214 包封的纳米乳在血浆和不同组织中的药代动力学特性得到了改善。此外,与溶液形式相比,纳米乳在体外具有更稳定的性质和更缓慢的药物释放。
本研究结果表明,该药物在纳米乳中的有效包封,与溶液形式相比,纳米乳显示出持续的血浆水平和增强的肿瘤递送。